A COMPLETE INTRODUCTORY TEXT TO THE FIELD OF PHARMACOGENOMICS A Doody's Core Title for 2015! The only pharmacogenomics resource to feature a global author team comprised of PharmDs, MDs, PhDs and social scientists, Pharmacogenomics offers an essential, highly accessible survey of this dynamic discipline. You will find thorough coverage of all need-to-know topics, from individual molecules to systemic diseases, plus anexamination of the latest technologies that are constantly reshaping the field. Pharmacogenomics is cohesively organized into two sections, the first of which reviewsbasic aspects…mehr
A COMPLETE INTRODUCTORY TEXT TO THE FIELD OF PHARMACOGENOMICS A Doody's Core Title for 2015! The only pharmacogenomics resource to feature a global author team comprised of PharmDs, MDs, PhDs and social scientists, Pharmacogenomics offers an essential, highly accessible survey of this dynamic discipline. You will find thorough coverage of all need-to-know topics, from individual molecules to systemic diseases, plus anexamination of the latest technologies that are constantly reshaping the field. Pharmacogenomics is cohesively organized into two sections, the first of which reviewsbasic aspects of pharmacogenomics, including ethics, regulatory, science, and drug metabolism, along with a "mini" course in molecular genetics and testing. The second section highlights the practical application of pharmacogenomics in cardiovascular medicine, immunology, neurology, and other specialties. FEATURES Important overview of general pharmacogenomics and pharmacogenetics concepts, including geneticvariation in signal transduction and targets, plus a review of the genetic concepts of pharmacogenomics Discussion of regulatory considerations in pharmacogenomics Focus on the role of health care professionals along with a review of related privacy issues,as well as broader ethical, legal, and social considerations In-depth chapters on drug metabolism and transporters Practical, step-by-step guidance on public access to pharmacogenomic testing and patient counseling Up-to-date coverage of non-genetic influences on pharmacogenomics Emphasis on gene-drug interactions Numerous tables and figures Chapter-ending references Concise learning objectives at the beginning of each chapter Case studies to familiarize you with the clinical relevance of pharmacogenomics in each specialtyHinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Joseph S. Bertino Jr., Pharm.D. is an Associate Professor of Clinical Pharmacology in Medicine at the College of Physicians and Surgeons, Columbia University, New York, NY. His research interests are varied and include work with vaccines, antimicrobial pharmacokinetics and pharmacodynamics, treatment of hypertension, pharmacogenetics and pharmacogenomics. Dr. Bertino received the Pharm.D. degree from SUNY at Buffalo. He has published over 100 original research papers, review articles and book chapters. His publications have included work in the area of antimicrobial pharmacokinetics, pharmacodynamics and toxicity, drug-drug interactions, general clinical pharmacology, vaccine pharmacology and the application of pharmacogenetics to the drug development process. Joseph D. Ma, PharmD is an Assistant Professor at the University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences. He received his Pharmacy Doctorate from the University of California, San Francisco. He then completed a 2-year fellowship in clinical pharmacology at Bassett Healthcare, Cooperstown, NY. Upon fellowship completion, Dr. Ma was employed at Amgen, Inc. and was responsible for phase I protocol development and study operational and managerial functions. Dr. Ma joined UCSD in 2007. He serves as co-coordinator for the winter quarter Therapeutics course and for a spring quarter elective titled Drug Discovery, Development, and Commercialization. His research interests are in examining pharmacokinetic and pharmacodynamic variability and in the optimization of drugs as probes to phenotype drug-metabolizing enzyme activity. Angela Kashuba, PharmD is an Associate Professor of Pharmacy at the University of North Carolina in Chappel Hill. Ms. Kashuba received two grants specifically on pharmcgenomics on the elderly. C. Lindsay DeVane, Pharm.D. is Professor of Psychiatry and Behavioral Sciences and Vice Chair for Research in the Department of Psychiatry at the Medical University of South Carolina (MUSC) in Charleston, SC. He directs the Laboratory of Drug Disposition and Pharmacogenetics in the Darby Children's Research Institute and oversees operation of the core laboratories of MUSC's General Clinical Research Center. Professor Uwe Fuhr MD, is Clinical Pharmacologist at University of Cologne, Cologne, Germany, Faculty of Medicine. He is a native of Saarbruecken, Germany, and attended Johann Wolfgang Goethe University in Frankfurt am Main, Germany, as an undergraduate in Medicine where he obtained state registration as a physician in 1987.
Inhaltsangabe
Section I. General Concepts 1. Developing Perspectives on Pharmacogenomics 2. Genetic Concepts of Pharmacogenomics: Basic Review of DNA, Genes, Polymorphisms, Haplotypes and Nomenclature 3. Analytical Methods to Identify Genetic Variations and Bioinformatics 4. Regulatory Considerations in Pharmacogenomics at EMA and US FDA 5. Ethical, Legal, and Social Issues Associated with Pharmacogenomics 6A. Pharmacogenetics of Cytochrome P450 6B. Phase II Drug-Metabolizing Enzymes 7. Drug Transporters 8. Nongenetic Influences on Drug Metabolism 9. Public Access to Pharmacogenomic Testing and Patient Counseling 10. Understanding the Use of Pharmacoeconomic Analysis to Assess the Economic Impact of Pharmacogenomic Testing Section II. Clinical Application of Pharmacogenomics 11. Cardiovascular Pharmacogenomics 12. Pharmacogenomics and Pharmacogenetics for Infectious Diseases 13. Pharmacogenomics in Oncology 14. Psychiatry and Addiction Medicine 15. Immunology,Transplantation,and Vaccines 16. Pharmacogenomics in Neurology 17A. Pharmacogenomics of Gastrointestinal Drugs: Focus on Proton Pump Inhibitors 17B. Genomics and the Kidney Index
Section I. General Concepts 1. Developing Perspectives on Pharmacogenomics 2. Genetic Concepts of Pharmacogenomics: Basic Review of DNA, Genes, Polymorphisms, Haplotypes and Nomenclature 3. Analytical Methods to Identify Genetic Variations and Bioinformatics 4. Regulatory Considerations in Pharmacogenomics at EMA and US FDA 5. Ethical, Legal, and Social Issues Associated with Pharmacogenomics 6A. Pharmacogenetics of Cytochrome P450 6B. Phase II Drug-Metabolizing Enzymes 7. Drug Transporters 8. Nongenetic Influences on Drug Metabolism 9. Public Access to Pharmacogenomic Testing and Patient Counseling 10. Understanding the Use of Pharmacoeconomic Analysis to Assess the Economic Impact of Pharmacogenomic Testing Section II. Clinical Application of Pharmacogenomics 11. Cardiovascular Pharmacogenomics 12. Pharmacogenomics and Pharmacogenetics for Infectious Diseases 13. Pharmacogenomics in Oncology 14. Psychiatry and Addiction Medicine 15. Immunology,Transplantation,and Vaccines 16. Pharmacogenomics in Neurology 17A. Pharmacogenomics of Gastrointestinal Drugs: Focus on Proton Pump Inhibitors 17B. Genomics and the Kidney Index
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826